You are here: Home: CCU 1 | 2006: Faculty disclosures
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-
the-art education. We assess potential conflicts of interest with faculty, planners and managers of
CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
validation process. The content of each activity is reviewed by both a member of the scientific staff
and an external independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development and
review of content for educational activities and report the following real or apparent conflicts of interest
for themselves (or their spouses/partners) that have been resolved through a peer review process:
Richard Kaderman, PhD, Neil Love, MD, Douglas Paley, Michelle Paley, MD, Marie Bialek, PharmD,
Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD and Kathryn Ault Ziel, PhD
— no real or apparent conflicts of interest to report; Sally Bogert, RNC, WHCNP — shareholder of
Amgen Inc. Research To Practice receives education grants from Abraxis Oncology, Amgen Inc,
AstraZeneca Pharmaceuticals LP, Biogen Idec, Genentech BioOncology, Genomic Health Inc, Roche
Laboratories Inc and Sanofi-Aventis, who have no influence on the content development of our educational
activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
of interest that have been resolved through a peer review process:
Dr Hurwitz — Consulting Fees and Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology,
Pfizer Inc, Roche Laboratories Inc; Speakers Bureau: Genentech BioOncology. Dr Enzinger — Consulting Fees: Daiichi Pharmaceutical Co Ltd, Genentech BioOncology, Pfizer Inc, Sanofi-Aventis. Dr Benson — Consulting Fees
and Contracted Research: Bristol-Myers Squibb Company, Genentech BioOncology, ImClone Systems, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
|